On September 30, 2025 Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) reported the signing of a memorandum of understanding (MOU) to advance online adaptive radiotherapy (OART) on the Accuray helical radiation treatment delivery platform (Press release, University of Wisconsin, SEP 30, 2025, View Source [SID1234656357]). As part of the MOU, the two parties outlined their intent to collaborate on clinical research, education and training, and adaptive technology development, to help empower medical care teams to raise the bar in the personalization and precision of cancer care.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I couldn’t be prouder to announce this proposed collaboration with the University of Wisconsin and the renowned team at their Department of Human Oncology. We share a mutual goal to expand the curative power of radiotherapy with technologies that not only help extend survivorship but also quality of life―and we believe OART can help to do just that. The proposed collaboration aims to leverage our respective strengths to reshape the overall OART experience for providers so that ultimately, clinical departments of all sizes can find it feasible to incorporate this advanced treatment option into their practice," said Mu Young Lee, SVP, Research & Product Development at Accuray.
University of Wisconsin–Madison researchers invented the first helical radiation delivery platform, the TomoTherapy System. It ushered in a new era in radiation medicine that enabled clinicians, for the first time, to leverage a system specifically designed for integrated 3D daily image-guidance with intensity-modulated radiation therapy (IG-IMRT) to increase the precision and accuracy of treatments and help better control patients’ cancer. Since the TomoTherapy System’s introduction, Accuray has continued to evolve the helical platform with the purpose of further enhancing its precision and accuracy, as well as introducing advances in the areas of image quality, speed, versatility, and workflow efficiencies.
"The origins of the TomoTherapy System began right here at UW–Madison, and our clinical researchers have deep experience in bringing future innovations from bench to bedside," said Nita Ahuja, MD, MBA, Dean of the school and Vice Chancellor for Medical Affairs at the University of Wisconsin–Madison. "This MOU focused on online adaptive radiotherapy for personalized, precision cancer care signifies our commitment to keeping patients at the center of our research efforts, while also allowing important translational medicine training opportunities for the next generation of clinical researchers and physician-scientists."